Ellermann Christian, Mengel Carlo, Wolfes Julian, Wegner Felix K, Rath Benjamin, Reinke Florian, Eckardt Lars, Frommeyer Gerrit
Department of Cardiology II (Electrophysiology), University Hospital Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.
Pharmaceutics. 2025 Mar 6;17(3):338. doi: 10.3390/pharmaceutics17030338.
: Recent studies reported an abbreviation of cardiac repolarization induced by sacubitril. Thus, the purpose of this study was to evaluate the electrophysiologic effects of sacubitril in the presence of drugs that shorten the QT interval. : 25 rabbit hearts were retrogradely perfused. After generating baseline data, hearts were allocated to two groups. In the first group ( = 12), the I opener pinacidil (1 µM) significantly reduced action potential duration at 90% of repolarization (APD), QT intervals and effective refractory periods (ERP). Additional administration of sacubitril (5 µM) slightly reduced APD. The digitalis glycoside ouabain (0.2 µM) significantly shortened repolarization duration and refractory periods. Additional infusion of sacubitril abbreviated repolarization duration and ERP. Ventricular vulnerability was assessed by delivering premature extra stimuli and burst stimulation. Significantly more ventricular arrhythmias occurred with pinacidil (26 episodes vs. 5 episodes under baseline conditions, < 0.05). Additional sacubitril treatment had no significant proarrhythmic effect (24 episodes). Ouabain alone did not provoke ventricular arrhythmias (6 episodes vs. 3 under baseline conditions, = ns) whereas additional sacubitril treatment significantly increased the occurrence of VT episodes (29 episodes, < 0.01). : Sacubitril abbreviates cardiac repolarization in ouabain-pretreated hearts. While sacubitril had no proarrhythmic effect in the presence of pinacidil, the combination of sacubitril and ouabain amplified the arrhythmic risk. The underlying mechanism is a further abbreviation of refractory periods and cardiac repolarization that facilitate ventricular arrhythmias. These findings add further evidence to the proarrhythmic capacity of digitalis glycosides in the presence of other drugs that influence cardiac repolarization.
近期研究报道了沙库巴曲可导致心脏复极化缩短。因此,本研究旨在评估在使用缩短QT间期药物的情况下沙库巴曲的电生理效应。25只兔心脏进行逆行灌注。在生成基线数据后,将心脏分为两组。在第一组(n = 12)中,I类开放剂吡那地尔(1 μM)显著缩短了复极化90%时的动作电位时程(APD)、QT间期和有效不应期(ERP)。额外给予沙库巴曲(5 μM)可轻微缩短APD。洋地黄苷哇巴因(0.2 μM)显著缩短复极化时程和不应期。额外输注沙库巴曲可缩短复极化时程和ERP。通过发放过早额外刺激和串刺激来评估心室易损性。吡那地尔诱发的室性心律失常明显更多(26次发作 vs. 基线条件下的5次发作,P < 0.05)。额外的沙库巴曲治疗无显著促心律失常作用(24次发作)。单独使用哇巴因未诱发室性心律失常(6次发作 vs. 基线条件下的3次发作,P = 无显著性差异),而额外的沙库巴曲治疗显著增加了室性心动过速发作的发生率(29次发作,P < 0.01)。沙库巴曲可缩短哇巴因预处理心脏的心脏复极化。虽然沙库巴曲在存在吡那地尔时无促心律失常作用,但沙库巴曲和哇巴因联合使用会增加心律失常风险。潜在机制是不应期和心脏复极化的进一步缩短,从而促进室性心律失常。这些发现为洋地黄苷在存在其他影响心脏复极化药物时的促心律失常能力提供了进一步证据。